Catalyst Pharmaceuticals Stock Technical Analysis
| CPRX Stock | USD 24.27 0.18 0.74% |
As of the 11th of February 2026, Catalyst Pharmaceuticals shows the Risk Adjusted Performance of 0.0914, mean deviation of 1.49, and Downside Deviation of 1.92. Catalyst Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Catalyst Pharmaceuticals Momentum Analysis
Momentum indicators are widely used technical indicators which help to measure the pace at which the price of specific equity, such as Catalyst, fluctuates. Many momentum indicators also complement each other and can be helpful when the market is rising or falling as compared to CatalystCatalyst Pharmaceuticals' Momentum analyses are specifically helpful, as they help investors time the market using mark points where the market can reverse. The reversal spots are usually identified through divergence between price movement and momentum.Catalyst Pharmaceuticals Analyst Consensus
| Target Price | Consensus | # of Analysts | |
| 34.57 | Strong Buy | 7 | Odds |
Most Catalyst analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Catalyst stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Catalyst Pharmaceuticals, talking to its executives and customers, or listening to Catalyst conference calls.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Catalyst Pharmaceuticals. Projected growth potential of Catalyst fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Catalyst Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 0.2 | Earnings Share 1.7 | Revenue Per Share | Quarterly Revenue Growth 0.153 | Return On Assets |
Understanding Catalyst Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects Catalyst's accounting equity. The concept of intrinsic value - what Catalyst Pharmaceuticals' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Catalyst Pharmaceuticals' price substantially above or below its fundamental value.
It's important to distinguish between Catalyst Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Catalyst Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Catalyst Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Catalyst Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Catalyst Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Catalyst Pharmaceuticals.
| 11/13/2025 |
| 02/11/2026 |
If you would invest 0.00 in Catalyst Pharmaceuticals on November 13, 2025 and sell it all today you would earn a total of 0.00 from holding Catalyst Pharmaceuticals or generate 0.0% return on investment in Catalyst Pharmaceuticals over 90 days. Catalyst Pharmaceuticals is related to or competes with Mineralys Therapeutics, Apellis Pharmaceuticals, Beam Therapeutics, Adaptive Biotechnologies, Scholar Rock, Ideaya Biosciences, and Recursion Pharmaceuticals. Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing ... More
Catalyst Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Catalyst Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Catalyst Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 1.92 | |||
| Information Ratio | 0.06 | |||
| Maximum Drawdown | 11.73 | |||
| Value At Risk | (3.20) | |||
| Potential Upside | 3.0 |
Catalyst Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Catalyst Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Catalyst Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Catalyst Pharmaceuticals historical prices to predict the future Catalyst Pharmaceuticals' volatility.| Risk Adjusted Performance | 0.0914 | |||
| Jensen Alpha | 0.1305 | |||
| Total Risk Alpha | (0) | |||
| Sortino Ratio | 0.062 | |||
| Treynor Ratio | 0.2343 |
Catalyst Pharmaceuticals February 11, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0914 | |||
| Market Risk Adjusted Performance | 0.2443 | |||
| Mean Deviation | 1.49 | |||
| Semi Deviation | 1.76 | |||
| Downside Deviation | 1.92 | |||
| Coefficient Of Variation | 937.17 | |||
| Standard Deviation | 1.98 | |||
| Variance | 3.93 | |||
| Information Ratio | 0.06 | |||
| Jensen Alpha | 0.1305 | |||
| Total Risk Alpha | (0) | |||
| Sortino Ratio | 0.062 | |||
| Treynor Ratio | 0.2343 | |||
| Maximum Drawdown | 11.73 | |||
| Value At Risk | (3.20) | |||
| Potential Upside | 3.0 | |||
| Downside Variance | 3.68 | |||
| Semi Variance | 3.1 | |||
| Expected Short fall | (1.57) | |||
| Skewness | 0.2921 | |||
| Kurtosis | 1.52 |
Catalyst Pharmaceuticals Backtested Returns
At this stage we consider Catalyst Stock to be very steady. Catalyst Pharmaceuticals secures Sharpe Ratio (or Efficiency) of 0.0574, which signifies that the company had a 0.0574 % return per unit of risk over the last 3 months. We have found twenty-eight technical indicators for Catalyst Pharmaceuticals, which you can use to evaluate the volatility of the firm. Please confirm Catalyst Pharmaceuticals' Downside Deviation of 1.92, risk adjusted performance of 0.0914, and Mean Deviation of 1.49 to double-check if the risk estimate we provide is consistent with the expected return of 0.1%. Catalyst Pharmaceuticals has a performance score of 4 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 0.86, which signifies possible diversification benefits within a given portfolio. Catalyst Pharmaceuticals returns are very sensitive to returns on the market. As the market goes up or down, Catalyst Pharmaceuticals is expected to follow. Catalyst Pharmaceuticals right now shows a risk of 1.82%. Please confirm Catalyst Pharmaceuticals potential upside, as well as the relationship between the accumulation distribution and period momentum indicator , to decide if Catalyst Pharmaceuticals will be following its price patterns.
Auto-correlation | 0.55 |
Modest predictability
Catalyst Pharmaceuticals has modest predictability. Overlapping area represents the amount of predictability between Catalyst Pharmaceuticals time series from 13th of November 2025 to 28th of December 2025 and 28th of December 2025 to 11th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Catalyst Pharmaceuticals price movement. The serial correlation of 0.55 indicates that about 55.0% of current Catalyst Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.55 | |
| Spearman Rank Test | 0.57 | |
| Residual Average | 0.0 | |
| Price Variance | 0.65 |
Catalyst Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Catalyst Pharmaceuticals Technical Analysis
The output start index for this execution was one with a total number of output elements of sixty. The Normalized Average True Range is used to analyze tradable apportunities for Catalyst Pharmaceuticals across different markets.
About Catalyst Pharmaceuticals Technical Analysis
The technical analysis module can be used to analyzes prices, returns, volume, basic money flow, and other market information and help investors to determine the real value of Catalyst Pharmaceuticals on a daily or weekly bases. We use both bottom-up as well as top-down valuation methodologies to arrive at the intrinsic value of Catalyst Pharmaceuticals based on its technical analysis. In general, a bottom-up approach, as applied to this company, focuses on Catalyst Pharmaceuticals price pattern first instead of the macroeconomic environment surrounding Catalyst Pharmaceuticals. By analyzing Catalyst Pharmaceuticals's financials, daily price indicators, and related drivers such as dividends, momentum ratios, and various types of growth rates, we attempt to find the most accurate representation of Catalyst Pharmaceuticals's intrinsic value. As compared to a bottom-up approach, our top-down model examines the macroeconomic factors that affect the industry/economy before zooming in to Catalyst Pharmaceuticals specific price patterns or momentum indicators. Please read more on our technical analysis page.
| 2023 | 2024 | 2025 | 2026 (projected) | Days Sales Outstanding | 49.05 | 48.61 | 55.9 | 45.49 | PTB Ratio | 4.61 | 3.4 | 3.91 | 3.71 |
Catalyst Pharmaceuticals February 11, 2026 Technical Indicators
Most technical analysis of Catalyst help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Catalyst from various momentum indicators to cycle indicators. When you analyze Catalyst charts, please remember that the event formation may indicate an entry point for a short seller, and look at different other indicators across different periods to confirm that a breakdown or reversion is likely to occur.
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0914 | |||
| Market Risk Adjusted Performance | 0.2443 | |||
| Mean Deviation | 1.49 | |||
| Semi Deviation | 1.76 | |||
| Downside Deviation | 1.92 | |||
| Coefficient Of Variation | 937.17 | |||
| Standard Deviation | 1.98 | |||
| Variance | 3.93 | |||
| Information Ratio | 0.06 | |||
| Jensen Alpha | 0.1305 | |||
| Total Risk Alpha | (0) | |||
| Sortino Ratio | 0.062 | |||
| Treynor Ratio | 0.2343 | |||
| Maximum Drawdown | 11.73 | |||
| Value At Risk | (3.20) | |||
| Potential Upside | 3.0 | |||
| Downside Variance | 3.68 | |||
| Semi Variance | 3.1 | |||
| Expected Short fall | (1.57) | |||
| Skewness | 0.2921 | |||
| Kurtosis | 1.52 |
Catalyst Pharmaceuticals February 11, 2026 Daily Trend Indicators
Traders often use several different daily volumes and price technical indicators to supplement a more traditional technical analysis when analyzing securities such as Catalyst stock. With literally thousands of different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 25,915 | ||
| Daily Balance Of Power | (0.32) | ||
| Rate Of Daily Change | 0.99 | ||
| Day Median Price | 24.32 | ||
| Day Typical Price | 24.30 | ||
| Price Action Indicator | (0.14) |
Additional Tools for Catalyst Stock Analysis
When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.